Artivion has halted the PROACT Xa clinical trial, which was designed to assess if patients with an On-X mechanical aortic valve could be maintained safely and effectively on apixaban versus warfarin.
The randomised, prospective trial enrolled subjects with an On-X aortic valve replacement to receive either warfarin or apixaban as the anticoagulant for preventing blood clots.
In April 2020, the trial commenced subject enrolment.
